CMBI: Raises Innovent Biologics (01801.HK) target price to HK$138.63; IBI3003 clinical data support its competitiveness in the MM TCE field

Zhitong Finance APP has learned that CMBI has issued a research report stating that Innovent Biologics (01801.HK) presented Phase I clinical data for IBI3003 in 102 patients with relapsed or refractory multiple myeloma (MM) at IMS 2026. IBI3003 is a BCMAGPRC5DCD3 trispecific T-cell engager (TCE) that has demonstrated positive early clinical results in patients with relapsed or refractory multiple myeloma, supporting its position among the leading assets in this field. The bank maintains its "Buy" rating and has raised its target price to HK$138.63.